




Investor Fact Sheet

Financial key figures 2023/24


(Audited Swiss GAAP FER figures)
in thousand CHF

	2023/24	in %	2022/23	in %	Veränderung	in %
Sales of goods and services group	548 457	100.0 %	497 460	100.0 %	50 997	10.3 %
thereof continuing business group	548 457	100.0 %	440 479	80.3 %	107 977	24.5 %
Ypsomed Delivery Systems (YDS)	385 152	70.2 %	307 807	61.9 %	77 345	25.1 %
Ypsomed Diabetes Care (YDC)	151 049	27.5 %	173 530	34.9 %	-22 481	-13.0 %
thereof continuing business YDC	151 049	27.5 %	116 550	23.4 %	34 499	29.6 %
Others	12 255	2.2 %	16 122	3.2 %	-3 867	-24.0 %
Gross profit	189 053	34.5 %	140 591	28.3 %	48 462	34.5 %
Operating profit group	86 219	15.7 %	60 594	12.2 %	25 625	42.3 %
thereof continuing business group	86 219	15.7 %	39 369	7.2 %	46 850	119.0 %
Financial income	4 835	0.9 %	3 164	0.6 %	1 672	52.8 %
Financial expenses	-9 183	-1.7 %	-7 121	-1.4 %	-2 062	29.0 %
Income taxes	-3 506	-0.6 %	-5 362	-1.1 %	1 857	-34.6 %
Net profit	78 366	14.3 %	51 275	10.3 %	27 091	52.8 %
Earnings per share in CHF	5.74		3.82		1.92	50.3 %
Operating profit	86 219	15.7 %	60 594	12.2 %	25 625	42.3 %
Depreciation and impairment of fixed assets	43 547		41 810		1 737	4.2 %
Amortisation and impairment of intangible assets	31 319		36 750		-5 431	-14.8 %
EBITDA (Operating profit before depreciation and amortisation)	161 085	29.4 %	139 154	28.0 %	21 931	15.8 %
Equity ratio in %	56.1 %		65.2 %		-9.2 %	
Investments in fixed assets	121 033		98 717		22 316	22.6 %
Investments in intangible assets	79 893		79 700		194	0.2 %
Number of employees	2 389		2 059		330	16.0 %
Number of full-time positions	2 296		1 978		317	16.0 %

Sales at group level



EBIT at group level



1 DiaExpert GmbH divested as per 31 December 2022

Further information on significant shareholders and shareholder groups as well as other financial figures of the Ypsomed Group can be found in the Annual Report 2023/24 and at www.ypsomed.ch.

Legal disclaimer: The information contained in this document has not been independently verified and no representation or warranty, expressed or implied, is made to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. Neither Ypsomed Holding AG, its advisors or representatives, nor their respective affiliates shall have any liability whatsoever for any loss whatsoever arising from any use of this document, or its content, or otherwise arising in connection with this document. This document does not constitute, or form part of, an offer to sell or a solicitation of an offer to purchase any shares and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. This document contains forward-looking statements which involve risks and uncertainties. These statements may be identified by such words as “may”, “plans”, “expects”, “believes” and similar expressions, or by their context. These statements are made on the basis of current knowledge and assumptions. Various factors could cause actual future results, performance or events to differ materially from those described in these statements. No obligation is assumed to update any forward-looking statements.